LT3294345T - Tpp1 vaisto formos ir cln2 ligos gydymo būdai - Google Patents

Tpp1 vaisto formos ir cln2 ligos gydymo būdai

Info

Publication number
LT3294345T
LT3294345T LTEPPCT/US2016/031074T LTUS2016031074T LT3294345T LT 3294345 T LT3294345 T LT 3294345T LT US2016031074 T LTUS2016031074 T LT US2016031074T LT 3294345 T LT3294345 T LT 3294345T
Authority
LT
Lithuania
Prior art keywords
tpp1
treatment
methods
pharmaceutical form
cln2 disease
Prior art date
Application number
LTEPPCT/US2016/031074T
Other languages
English (en)
Lithuanian (lt)
Inventor
Thomas Lester
Saeed Moshashaee
Augustus Okhamafe
Charles O'neill
Original Assignee
Biomarin Pharmaceutical Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biomarin Pharmaceutical Inc. filed Critical Biomarin Pharmaceutical Inc.
Publication of LT3294345T publication Critical patent/LT3294345T/lt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4813—Exopeptidases (3.4.11. to 3.4.19)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/485—Exopeptidases (3.4.11-3.4.19)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/14—Dipeptidyl-peptidases and tripeptidyl-peptidases (3.4.14)
    • C12Y304/14009—Tripeptidyl-peptidase I (3.4.14.9)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Anesthesiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
LTEPPCT/US2016/031074T 2015-05-08 2016-05-05 Tpp1 vaisto formos ir cln2 ligos gydymo būdai LT3294345T (lt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562158789P 2015-05-08 2015-05-08
US201662300171P 2016-02-26 2016-02-26
PCT/US2016/031074 WO2016182862A1 (en) 2015-05-08 2016-05-05 Tpp1 formulations and methods for treating cln2 disease

Publications (1)

Publication Number Publication Date
LT3294345T true LT3294345T (lt) 2024-02-12

Family

ID=57222195

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEPPCT/US2016/031074T LT3294345T (lt) 2015-05-08 2016-05-05 Tpp1 vaisto formos ir cln2 ligos gydymo būdai

Country Status (25)

Country Link
US (3) US10279015B2 (OSRAM)
EP (2) EP4327873A3 (OSRAM)
JP (3) JP6931330B2 (OSRAM)
KR (1) KR102375051B1 (OSRAM)
CN (2) CN107847615B (OSRAM)
AU (1) AU2016262434B2 (OSRAM)
CA (1) CA2984448A1 (OSRAM)
CL (1) CL2017002825A1 (OSRAM)
DK (1) DK3294345T3 (OSRAM)
ES (1) ES2968375T3 (OSRAM)
FI (1) FI3294345T3 (OSRAM)
HR (2) HRP20240050T1 (OSRAM)
HU (1) HUE065649T2 (OSRAM)
IL (3) IL255307B (OSRAM)
LT (1) LT3294345T (OSRAM)
MX (1) MX2017014204A (OSRAM)
PL (1) PL3294345T3 (OSRAM)
PT (1) PT3294345T (OSRAM)
RS (1) RS65101B1 (OSRAM)
RU (1) RU2733464C2 (OSRAM)
SI (1) SI3294345T1 (OSRAM)
SM (1) SMT202400026T1 (OSRAM)
TW (1) TWI752907B (OSRAM)
WO (1) WO2016182862A1 (OSRAM)
ZA (1) ZA201707373B (OSRAM)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI752907B (zh) * 2015-05-08 2022-01-21 美商拜奧馬林製藥公司 用於治療cln2疾病之tpp1調配物及方法
EP3607320A4 (en) 2017-04-03 2021-04-21 The Regents of the University of California COMPOSITIONS AND METHODS OF DIAGNOSING Pancreatic Cancer
WO2019060298A1 (en) 2017-09-19 2019-03-28 Neuroenhancement Lab, LLC METHOD AND APPARATUS FOR NEURO-ACTIVATION
US11717686B2 (en) 2017-12-04 2023-08-08 Neuroenhancement Lab, LLC Method and apparatus for neuroenhancement to facilitate learning and performance
US11478603B2 (en) 2017-12-31 2022-10-25 Neuroenhancement Lab, LLC Method and apparatus for neuroenhancement to enhance emotional response
US12280219B2 (en) 2017-12-31 2025-04-22 NeuroLight, Inc. Method and apparatus for neuroenhancement to enhance emotional response
US11364361B2 (en) 2018-04-20 2022-06-21 Neuroenhancement Lab, LLC System and method for inducing sleep by transplanting mental states
CN113382683A (zh) 2018-09-14 2021-09-10 纽罗因恒思蒙特实验有限责任公司 改善睡眠的系统和方法
US11786694B2 (en) 2019-05-24 2023-10-17 NeuroLight, Inc. Device, method, and app for facilitating sleep
US20220381784A1 (en) * 2019-06-07 2022-12-01 The Regents Of The University Of California Systems comprising substrates and methods of using the same for detection of pancreatic cancers
SMT202400315T1 (it) * 2019-08-29 2024-09-16 Biomarin Pharm Inc Metodi per il trattamento della malattia cln2 in soggetti pediatrici
IT201900023142A1 (it) * 2019-12-05 2021-06-05 Sifi Spa Composizione topica oculare contenente metaboliti della fermentazione di lactobacillus
US20230060797A1 (en) * 2021-09-02 2023-03-02 Jcr Pharmaceuticals Co., Ltd. Therapeutic compound for neuronal ceroid lipofuscinosis
CN117731312A (zh) 2022-09-13 2024-03-22 上海联影医疗科技股份有限公司 一种医学图像的扫描方法和系统

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6302685B1 (en) 1997-09-16 2001-10-16 University Of Medicine And Dentistry Of New Jersey Human lysosomal protein and methods of its use
US20020006400A1 (en) 2000-05-11 2002-01-17 Peter Lobel Recombinant human CLN2 protein and methods of its production and use
MXPA03010341A (es) * 2001-05-18 2004-03-10 Solvay Pharm Gmbh Uso de compuestos con actividad inhibitoria de epn/mp combinada en la preparacion de medicamentos.
AU2002362436A1 (en) * 2001-10-03 2003-04-14 Rigel Pharmaceuticals, Inc. Modulators of lymphocyte activation and migration
CA2388659A1 (en) * 2002-05-31 2003-11-30 Mcgill University Phospholipase a2 expression and activity and use thereof for diagnosis, prognostication, prevention and treatment of neural inflammatory and demyelinating disease
US7442372B2 (en) 2003-08-29 2008-10-28 Biomarin Pharmaceutical Inc. Delivery of therapeutic compounds to the brain and other tissues
US20110166074A1 (en) 2006-10-18 2011-07-07 Cornell Research Foundation, Inc. Cln2 treatment of alzheimer's disease
CA2721135A1 (en) * 2007-06-13 2008-12-24 Wayne State University Board Of Governors A zwitterion solution for low-volume therapeutic delivery
EP2333074A1 (en) * 2009-12-14 2011-06-15 Robert Steinfeld Substances and methods for the treatment of lysosmal storage diseases
WO2012015910A2 (en) * 2010-07-28 2012-02-02 Allon Therapeutics Inc. Use of adnf polypeptides for treating neurodegenerative diseases
WO2012177929A2 (en) * 2011-06-24 2012-12-27 Amylin Pharmaceuticals, Inc. Methods for treating diabetes with extended release formulations of glp-1 receptor agonists
US20150000936A1 (en) * 2011-12-13 2015-01-01 Schlumberger Technology Corporation Energization of an element with a thermally expandable material
US20140377244A1 (en) 2011-12-23 2014-12-25 Shire Human Genetic Therapies, Inc. Stable formulations for cns delivery of arylsulfatase a
ES2679374T3 (es) * 2012-11-27 2018-08-24 Biomarin Pharmaceutical Inc. Proteínas de fusión terapéuticas dirigidas de enzima lisosómica y usos de las mismas
US9750712B2 (en) 2012-12-07 2017-09-05 Rush University Medical Center Composition and method for treating neuronal ceroid lipofuscinosis
RU2018128780A (ru) 2013-07-26 2018-12-05 Юниверсити Оф Айова Рисерч Фаундейшн Способы и композиции для лечения болезней мозга
TWI752907B (zh) 2015-05-08 2022-01-21 美商拜奧馬林製藥公司 用於治療cln2疾病之tpp1調配物及方法

Also Published As

Publication number Publication date
HRP20171905B1 (hr) 2023-03-17
IL299024B2 (en) 2025-12-01
US10279015B2 (en) 2019-05-07
EP4327873A2 (en) 2024-02-28
SI3294345T1 (sl) 2024-03-29
US10758598B2 (en) 2020-09-01
RS65101B1 (sr) 2024-02-29
MX2017014204A (es) 2018-07-06
CN114225018A (zh) 2022-03-25
KR102375051B1 (ko) 2022-03-15
JP2024026739A (ja) 2024-02-28
SMT202400026T1 (it) 2024-03-13
TW201704469A (zh) 2017-02-01
US20200353059A1 (en) 2020-11-12
IL299024B1 (en) 2025-08-01
AU2016262434A1 (en) 2017-11-16
CN107847615A (zh) 2018-03-27
IL273913B2 (en) 2023-06-01
RU2733464C2 (ru) 2020-10-01
JP6931330B2 (ja) 2021-09-01
EP3294345A4 (en) 2019-01-16
BR112017023805A2 (pt) 2018-07-31
TWI752907B (zh) 2022-01-21
JP2021175760A (ja) 2021-11-04
AU2016262434B2 (en) 2022-06-02
CN107847615B (zh) 2022-01-25
PT3294345T (pt) 2024-01-18
EP4327873A3 (en) 2024-05-01
WO2016182862A1 (en) 2016-11-17
CL2017002825A1 (es) 2018-06-22
HK1250479A1 (en) 2018-12-21
US11229687B2 (en) 2022-01-25
RU2017142727A3 (OSRAM) 2019-12-11
DK3294345T3 (da) 2024-01-22
PL3294345T3 (pl) 2024-07-01
ZA201707373B (en) 2019-02-27
HUE065649T2 (hu) 2024-06-28
JP7421520B2 (ja) 2024-01-24
FI3294345T3 (fi) 2024-01-15
US20160324942A1 (en) 2016-11-10
IL273913A (en) 2020-05-31
KR20180004158A (ko) 2018-01-10
CA2984448A1 (en) 2016-11-17
RU2017142727A (ru) 2019-06-10
EP3294345A1 (en) 2018-03-21
EP3294345B1 (en) 2023-10-18
HRP20240050T1 (hr) 2024-03-29
HRP20171905A2 (hr) 2018-05-18
US20190216905A1 (en) 2019-07-18
IL255307A0 (en) 2017-12-31
ES2968375T3 (es) 2024-05-09
JP2018521964A (ja) 2018-08-09
IL255307B (en) 2021-03-25
IL299024A (en) 2023-02-01

Similar Documents

Publication Publication Date Title
LT3294345T (lt) Tpp1 vaisto formos ir cln2 ligos gydymo būdai
LT3672954T (lt) Junginiai, jų druskos ir jų naudojimas ligoms gydyti
IL257663B (en) Oral care compositions and methods of use
EP3681479A4 (en) METHOD OF ADMINISTRATION AND TREATMENT
HUE053309T2 (hu) Új sók és gyógyászati készítmények gyulladásos betegségek kezelésére
IL258476A (en) Prevention, treatment and reversal of disease using therapeutically effective amounts of activated fatty acids
LT3681483T (lt) Terapinio baltymo farmacinės formos liofilizavimo būdas
IL269083A (en) Methods for preventing and treating heart disease
ZA201800037B (en) Diagnosis and treatment of infectious disease
LT3119384T (lt) Intrahepatinių cholestazinių ligų gydymas
LT3242676T (lt) Oksitocino vaistinės formos, kurių sudėtyje yra magnio, ir jų naudojimo būdai
HUE062784T2 (hu) Indolinon vegyületek és alkalmazásuk fibrotikus betegségek kezelésében
IL270900A (en) Treatment of cutaneous disorders
IL252779A0 (en) Prevention and treatment of inflammatory conditions
LT3302499T (lt) Mitochondrinių ligų gydymas
BR112016028653A2 (pt) métodos de tratamento de doenças e distúrbios neurodesenvolvimentais
IL263076B (en) Treatment of skin lesions
KR20180085033A (ko) 피부 질환 치료용 약학적 제형 및 이의 제조 방법
HUE054653T2 (hu) Trazodon és gabapentin kombinációja fájdalom kezelésére
EP3368512C0 (en) INDOLINE DERIVATIVES FOR THE TREATMENT AND/OR PREVENTION OF FIBROTIC DISEASES
KR101583452B9 (ko) 위장질환 치료용 의약 조성물
LT3137093T (lt) Alzheimerio ligos (ad) gydymas ir prevencija
GB201621398D0 (en) Treatment of emt-associated disease
LT3383402T (lt) Farmacinė kompozicija, apimanti darunavirą, ir jos gamybos būdas
GB201609529D0 (en) Diagnosis and treatment of infectious disease